Growing research and development activities in genomics along with emergence of advanced genetic platform such as next-generation sequencing (NGS) continue to influence production of monoclonal antibodies. Additionally, cost efficient nature of NGS technology has fuelled its adoption in carrying out research apropos to development of monoclonal antibodies.
Rising Investments and Clinical Trials to Give an Impetus to the Monoclonal Antibodies Market
Being a fast emerging therapy, monoclonal antibodies are used as a vital tool in treating chronic diseases such as cancer, inflammatory diseases, autoimmune diseases and other infectious diseases. Inclination towards this therapy is gradually rising translating in steady sales of new formulations such as Humira and Herceptin. This aspect continues to encourage pharmaceutical companies to largely invest in research of monoclonal antibodies and their trials. For instance, in 2021 AstraZeneca conducted phase 3 trial for its Tezepelumab that is used for treating atopic dermatitis and asthma. Such pipeline trials are likely to drive the growth of the monoclonal antibodies market in the following years.
Humanized monoclonal antibodies are expected to witness significant traction in the years to follow. They are used in the treatment of autoimmune, cancer and inflammatory diseases. They are considered as a suitable therapy for hypoxic tumors and can be used in treatment of primary tumors and to suppress metastases formation.
Increasing Use in Cancer Treatment to Augment Growth of the Monoclonal Antibodies Market
Use of monoclonal antibodies in treating various types of cancers has been increasing since the recent past. This is mainly due to increasing cancer cases worldwide coupled with advantages of monoclonal antibodies in cancer treatment. According to World Health Organization (WHO), cancer cases worldwide are expected to increase significantly to touch 24.1 million by end of 2030 from 18 million cases observed in 2018. This has triggered the use of novel treatment methods that will have a mild impact on the patient but will prove effective against cancer cells. Monoclonal antibodies, as compared to chemotherapy and other cancer treating methods, are non-toxic and highly effective in diagnosis and treatment of various cancer types. In this backdrop, growing use of monoclonal antibodies in treatment of cancer is expected to highly contribute to the valuation of the monoclonal antibodies market on the global front.
North America to Account for a Significant Share in the Monoclonal Antibodies Market
The developed countries in North America have accounted for a significant share in the monoclonal antibodies market and are expected to maintain status quo in the following years. Various factors propelling growth of the monoclonal antibodies in North America include presence of advanced healthcare system and infrastructure, increasing funding by government for research and development of novel therapies and rising geriatric population. Diseases associated with geriatric population such as infectious diseases and chronic ailments such as cancer have triggered the use of monoclonal antibodies.
Governments are collaborating with pharmaceutical companies to facilitate development of monoclonal antibodies in the region. For instance, in 2020, Eli Lilly and Government of Canada signed a contract for commercialization of Bamlanivimab, a monoclonal antibody therapy for SARS-CoV-2. 26,000 initial doses of this monoclonal antibody developed by Eli Lilly were recorded. Likewise, National Institute of Health and similar organizations are also involved in the development of monoclonal antibodies and have achieved few breakthroughs. For example, in 2020, NIH (National Institute of Health) was successful in launching a clinical trial for two crucial treatments of SARS-CoV-2 with the use of monoclonal antibodies. Such developments and favorable support from government continues to influence the growth of the monoclonal antibodies market in the region.
Monoclonal Antibodies Market: Competitive Scenario
Companies in the monoclonal antibodies market have been developing new monoclonal antibodies to fight against chronic diseases. Moreover, their new formulations are being analyzed and approved by authorities, thus influencing market growth. In August 2020, the US FDA (Food and Drug Administration) gave approval to BLENREP (belantamab mafodotin-blmf) developed by GlaxoSmithKline for treating refractory or relapsed multiple myeloma. Likewise, same year in December, US FDA approved MARGENZATM developed by MacroGenics for the treatment of pretreated metastatic breast cancer that is HER2 positive.
Few of the key players in the monoclonal antibodies market include F Hoffmann-La Roche AG, Amgen Inc., Merck Group, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company, Daiichi Sankyo Company and Alexion Pharmaceuticals Inc.
Global Monoclonal Antibodies Market is Segmented as Below:
By Production Method
By End Users
Key Elements Included In The Study: Global Monoclonal Antibodies Market
Post Sale Support, Research Updates & Offerings
We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.
Under uncertainty, traditional approaches to strategic planning can be downright dangerous. True ambiguity is no basis to forecast the future – degree of risk, the magnitude of circumstances, conditions and consequences are not known or unpredictable. To avoid dangerous binary views of uncertainty; strategic posture, moves and actions through market research is the best bet.Read more